{"id":"diphenhydramine-iv","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Drowsiness/sedation"},{"rate":"5-20","effect":"Anticholinergic effects (dry mouth, urinary retention)"},{"rate":"5-15","effect":"Dizziness"},{"rate":"2-10","effect":"Headache"},{"rate":"1-5","effect":"Paradoxical excitation (especially in children)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diphenhydramine competitively antagonizes H1 histamine receptors on various tissues, preventing histamine-mediated effects such as itching, urticaria, and allergic reactions. The IV formulation provides rapid onset of action for acute allergic reactions and anaphylaxis. It also has anticholinergic and sedating properties due to central nervous system penetration.","oneSentence":"Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:56.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute allergic reactions"},{"name":"Anaphylaxis (adjunctive therapy)"},{"name":"Urticaria and pruritus"},{"name":"Allergic rhinitis"}]},"trialDetails":[{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT04375384","phase":"PHASE2","title":"Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma","enrollment":38},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT05627232","phase":"PHASE1","title":"Tazemetostat and Palbociclib With CPX-351for R/R AML","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-08-28","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT06211335","phase":"PHASE1","title":"Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-12-07","conditions":"Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT06043323","phase":"PHASE2","title":"A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-08","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT05896228","phase":"PHASE2","title":"Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Benjamin T Diamond, MD","startDate":"2024-02-20","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT07435311","phase":"PHASE1","title":"A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-06-15","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":118},{"nctId":"NCT07435324","phase":"PHASE3","title":"A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"R-Pharm","startDate":"2024-08-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":161},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07268248","phase":"NA","title":"1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study","status":"NOT_YET_RECRUITING","sponsor":"Paul Peng, MD PhD MSCR","startDate":"2026-06","conditions":"Allergic Reaction to Contrast Media, Hypersensitivity Reaction, Computed Tomography","enrollment":540},{"nctId":"NCT04432597","phase":"PHASE1, PHASE2","title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-11","conditions":"HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer","enrollment":39},{"nctId":"NCT04544436","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-26","conditions":"Multiple Sclerosis","enrollment":864},{"nctId":"NCT06074588","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-12","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":556},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT06083571","phase":"PHASE2","title":"Intranasal Ketorolac Trial","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2024-01-01","conditions":"Headache, Migraine","enrollment":41},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":"Hepatitis B","enrollment":58},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":"Hepatitis B, Hepatitis D","enrollment":79},{"nctId":"NCT02363946","phase":"PHASE1","title":"A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":"Alpha-1 Antitrypsin Deficiency","enrollment":65},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT04963296","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-26","conditions":"Systemic Lupus Erythematosus","enrollment":303},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT04548999","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":769},{"nctId":"NCT06120673","phase":"PHASE3","title":"REmission in Membranous Nephropathy International Trial (REMIT)","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2025-10-31","conditions":"Primary Membranous Nephropathy","enrollment":""},{"nctId":"NCT05977998","phase":"PHASE2","title":"A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-09-08","conditions":"Gastric Adenocarcinoma, Carcinomatosis","enrollment":30},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT04668833","phase":"PHASE2","title":"ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-29","conditions":"Solid Tumor Malignancies","enrollment":26},{"nctId":"NCT04456439","phase":"","title":"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Mesoblast International Sàrl","startDate":"","conditions":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)","enrollment":""},{"nctId":"NCT05285813","phase":"PHASE2","title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-05-06","conditions":"AML, MDS","enrollment":42},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT03493945","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-01","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm","enrollment":59},{"nctId":"NCT04294459","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-06-18","conditions":"Immune System Disorder","enrollment":23},{"nctId":"NCT03598426","phase":"PHASE3","title":"Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2018-08-08","conditions":"Hypersensitivity Reactions","enrollment":90},{"nctId":"NCT04862585","phase":"PHASE2, PHASE3","title":"Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-10-07","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8","enrollment":130},{"nctId":"NCT00573599","phase":"NA","title":"Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, Portsmouth","startDate":"2007-02","conditions":"Acute Migraine Headache","enrollment":""},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT05779930","phase":"EARLY_PHASE1","title":"Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-10","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory","enrollment":12},{"nctId":"NCT05232825","phase":"PHASE3","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-03","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":236},{"nctId":"NCT02098499","phase":"PHASE4","title":"Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, Portsmouth","startDate":"2013-06-12","conditions":"Migraine Headaches, Nausea, Restlessness","enrollment":""},{"nctId":"NCT03805932","phase":"PHASE1","title":"Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-03","conditions":"Hairy Cell Leukemia","enrollment":18},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT04165096","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-01-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":128},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT03448393","phase":"PHASE1","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-26","conditions":"Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma","enrollment":54},{"nctId":"NCT03554473","phase":"PHASE1, PHASE2","title":"M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-11","conditions":"Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04765449","phase":"PHASE1","title":"Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2021-09-15","conditions":"Covid19","enrollment":30},{"nctId":"NCT05365893","phase":"EARLY_PHASE1","title":"PHL Treatment in Pancreatic Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2021-10-20","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":20},{"nctId":"NCT04599634","phase":"PHASE1","title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-16","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma","enrollment":11},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT06557330","phase":"PHASE2","title":"MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-06","conditions":"Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":24},{"nctId":"NCT03030417","phase":"PHASE1","title":"Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-27","conditions":"Solid Tumors, Lymphoma","enrollment":36},{"nctId":"NCT03836014","phase":"PHASE3","title":"Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-25","conditions":"Multiple Myeloma in Relapse","enrollment":436},{"nctId":"NCT03472872","phase":"PHASE4","title":"A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache","status":"WITHDRAWN","sponsor":"Corewell Health South","startDate":"2017-09-05","conditions":"Headache","enrollment":""},{"nctId":"NCT05768919","phase":"PHASE1, PHASE2","title":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","status":"RECRUITING","sponsor":"SignPath Pharma, Inc.","startDate":"2023-03-03","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT06702670","phase":"PHASE2, PHASE3","title":"Anticholinergics for Cervical Edema in Labor","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-12-01","conditions":"Labor Dystocia","enrollment":200},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT06539806","phase":"NA","title":"Clinical Study Evaluating the Effect of Losartan","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-07-20","conditions":"Pancreatic Cancer","enrollment":90},{"nctId":"NCT06084845","phase":"PHASE2","title":"Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-04-12","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03185130","phase":"PHASE4","title":"Intravenous Fluids in Benign Headaches Trial","status":"COMPLETED","sponsor":"University Medical Center of Southern Nevada","startDate":"2017-05-16","conditions":"Headache","enrollment":58},{"nctId":"NCT02688985","phase":"PHASE3","title":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-04-29","conditions":"Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive","enrollment":131},{"nctId":"NCT04580121","phase":"PHASE1","title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-11-04","conditions":"Acute Myeloid Leukemia","enrollment":59},{"nctId":"NCT00445965","phase":"PHASE2","title":"Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-01","conditions":"Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer","enrollment":78},{"nctId":"NCT05013437","phase":"EARLY_PHASE1","title":"Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma","status":"WITHDRAWN","sponsor":"Koen van Besien","startDate":"2023-09","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02339155","phase":"PHASE4","title":"Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2015-02-24","conditions":"Infections, Bacterial","enrollment":573},{"nctId":"NCT02735343","phase":"PHASE3","title":"The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine","status":"TERMINATED","sponsor":"Mike O'Callaghan Military Hospital","startDate":"2016-08","conditions":"Headache","enrollment":5},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02023164","phase":"PHASE3","title":"Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2013-07","conditions":"Acute Urticaria","enrollment":36},{"nctId":"NCT05828147","phase":"PHASE4","title":"Anti-CD20 Antibodies for Treatment of SLE-PAH","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2023-05-25","conditions":"Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension","enrollment":50},{"nctId":"NCT04840615","phase":"PHASE1","title":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-11","conditions":"Mesothelioma","enrollment":2},{"nctId":"NCT00242814","phase":"PHASE4","title":"Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11-03","conditions":"Hypertension, Metabolic Syndrome X","enrollment":100},{"nctId":"NCT03689894","phase":"PHASE1, PHASE2","title":"Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2019-04-11","conditions":"Chronic Graft-versus-host-disease","enrollment":2},{"nctId":"NCT05673590","phase":"PHASE3","title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2023-05-12","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":612},{"nctId":"NCT04660799","phase":"PHASE2","title":"A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-24","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Diphenhydramine IV","genericName":"Diphenhydramine IV","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diphenhydramine is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses. Used for Acute allergic reactions, Anaphylaxis (adjunctive therapy), Urticaria and pruritus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}